Ground-breaking new research suggests that dramatically lower doses or shorter courses of revolutionary immunotherapy drugs could be highly effective. This finding may eventually pave the way for wider global access to life-saving cancer treatments. Lower-dose immunotherapy trials are showing promising potential. Drugs like Merck & Co’s Keytruda and Bristol Myers Squibb Co’s Opdivo have transformed oncology. They boost survival rates…